The Role of Lipid Rafts and Membrane Androgen Receptors in Androgen’s Neurotoxic Effects

Oluwadarasimi Fadeyibi¹, Nataliya Rybalchenko¹, Steve Mabry¹, Dianna H. Nguyen², and Rebecca L. Cunningham¹

¹Department of Pharmaceutical Sciences, School of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas 76107

²Department of Physiology & Anatomy, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, Texas 76107

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Address correspondence and reprint requests to: Rebecca L. Cunningham, PhD, Department of Pharmaceutical Sciences, University of North Texas Health Science Center, 3400 Camp Bowie Boulevard, Fort Worth, TX 76107-2699. ORCID ID #: 0000-0001-5984-5516.

Email: Rebecca.Cunningham@unthsc.edu

Grant and fellowship support: NIH R01 NS0091359 to RLC.

Disclosure statement: The authors have nothing to disclose.
Abstract

Sex differences have been observed in multiple oxidative stress associated neurodegenerative diseases. Androgens, such as testosterone, through a membrane androgen receptor (mAR), AR45, localized to lipid rafts in the plasma membrane can exacerbate oxidative stress. The goal of this study is to determine if interfering with mAR localization to cholesterol-rich lipid rafts decreases androgen induced neurotoxicity under oxidative stress environments. We hypothesize that cholesterol-rich caveolar lipid rafts are necessary for androgens to induce oxidative stress generation in neurons via the mAR localized within the plasma membrane. Nystatin was used to sequester cholesterol and thus decrease cholesterol-rich caveolar lipid rafts in a neuronal cell line (N27 cells). Nystatin was applied prior to testosterone exposure in oxidative stressed N27 cells. Cell viability, endocytosis, and protein analysis of oxidative stress, apoptosis, and mAR localization were conducted. Our results show that the loss of lipid rafts via cholesterol sequestering blocked androgen-induced oxidative stress in cells by decreasing the localization of mAR to caveolar lipid rafts.

Keywords: AR45, oxidative stress, apoptosis, membrane androgen receptor, nystatin, caveolin-1, testosterone, lipid rafts, endocytosis, statin, aromatase
Introduction

Sex differences have been observed in neurodegenerative diseases, such as Alzheimer’s Disease, Parkinson’s disease, Lewy Body Dementia, and vascular dementia. Men have a higher risk of vascular dementia, Parkinson’s disease, and Lewy Body Dementia than women (1,2). Common risk factors for these neurodegenerative diseases are cardiovascular diseases, such as hypertension (3). Cardiovascular diseases can increase oxidative stress (OS) (4), which can increase cellular vulnerability. Interestingly, cardiovascular disease is higher in men than pre-menopausal women (5). After menopause, cardiovascular diseases increase in women (6). Therefore, men exhibit a higher OS load than pre-menopausal women, which could lead to increased cellular vulnerability in men. Further, this increased OS load in men is chronic as it generally occurs at middle-age and is sustained throughout aging (7), whereas the OS load is more acute in post-menopausal women. Interestingly, hypertension that is higher in men than women (5) has been associated with cognitive decline later in life (8). Therefore, chronic OS burden that is generally observed in men may increase the risk for neurodegenerative disorders, such as vascular dementia.

Vascular dementia, a heterogeneous group of brain disorders, is a form of cognitive decline resulting from cerebrovascular disease in small or large vessels. Diseases, such as hypertension, obesity, diabetes, and hyperlipidemia (high cholesterol), can increase OS levels that can lead to cerebrovascular impairment and consequently vascular dementia (9). Vascular dementia is the second most common type of dementia (10), causing approximately 20% of known dementia cases (11). According to The World Health Organization, an estimate of 35.6 million people have dementia, and this number is expected to triple by 2050 (12). Approximately 7.7 million new cases of dementia are diagnosed every year, therefore causing a great burden on families, caregivers, and society (13).

OS is a hallmark common to all these disorders (14). It is possible that the effects of sex hormones on OS could mediate these sex differences. Estrogen, the major female sex hormone, is an antioxidant...
Many studies have shown that estrogen decreases OS by binding to estrogen receptors and upregulating the expression of antioxidant enzymes via intracellular signaling pathways (15). Generally, estrogen has been shown to have protective effects in many neurodegenerative diseases (16). Unlike estrogen, the major male sex hormone, testosterone, can have diverse effects on OS. Testosterone can be aromatized to an estrogen and protect cells from subsequent OS damage (17). In contrast, testosterone can be reduced to dihydrotestosterone (DHT) and increase OS (17). How testosterone impacts the brain is dependent on the health of the brain, such as basal OS levels. If OS levels are low, then androgens are protective against subsequent OS related stressors (17). If OS levels are high, then androgens can exacerbate OS damage (17).

In several cell types, such as dopaminergic cells, hippocampal cells, and cerebral cortical cells, the membrane androgen receptor (mAR) is localized to plasma membrane lipid rafts (18), which is a cholesterol-rich microdomain involved in cellular signaling (e.g., endocytosis and intracellular cascades) (19). This mAR present in the lipid rafts is an androgen receptor variant missing the N-terminus domain that is called AR45. AR45 has been observed to reside within caveolin-1 lipid rafts of neuronal N27 cells and brain tissue from young and middle-aged rats (18). Within these lipid rafts, this mAR forms a complex with one of the major OS cellular generators, NADPH oxidase (20). The involvement of the lipid rafts has been identified in several diseases including Alzheimer’s Disease, Parkinson’s Disease, and vascular dementia (21).

Since lipid rafts are composed of cholesterol, lipid raft expression in plasma membranes can be decreased using statins. Statins are a class of drugs that blocks the conversion of Hydroxy-methylglutaryl-coenzyme A (HMG-CoA) to mevalonic acid in the mevalonate pathway, thus they are referred to as HMG-CoA reductase inhibitors (22). Statins are used for lowering serum cholesterol levels and other cardiovascular interventions (23). There is evidence showing that individuals with hypertension and hypercholesterolemia, resulting from high levels of cholesterol, are at a higher risk
for vascular dementia and Alzheimer’s Disease (24,25). Since statins may decrease neurodegenerative disease risk and progression by lowering cholesterol levels (26,27), recent studies have focused on understanding the efficacy of statins in the prevention of neurodegenerative diseases. Currently, there are no therapeutic drugs for many neurodegenerative diseases, such as vascular dementia. However, epidemiological studies indicate that statins are associated with decreased risk of these diseases (28). In a meta-analysis that was comprised of observational studies and a randomized control study, it was observed that statins were associated with decreased cognitive impairment disorders (28), thus, repurposing statins for neurodegenerative disease therapeutics could be advantageous.

The goal of this study is to determine if interfering with mAR-AR45 localization to cholesterol-rich lipid rafts decreased androgen induced neurotoxicity under OS environments. To decrease lipid rafts, we use nystatin as a cholesterol sequestering agent (29).

Materials and Methods

Reagents

Testosterone (A6950-000) was obtained from Steraloids. Goat anti-rabbit (sc-2004) secondary antibody, goat anti-mouse (sc-2005) secondary antibody, androgen receptor C-19 (sc-7305) primary antibody that targets the C-terminus domain, androgen receptor N-20 (sc-816) primary antibody that targets the N-terminus domain, and estrogen receptor alpha MC-20 (sc-542) primary antibody were obtained from Santa Cruz. Caveolin-1 (3267) primary antibody was obtained from Cell Signaling. Beta Actin (GTX629630) primary antibody was obtained from GeneTex. Aromatase antibody (ab18995) was purchased from Abcam. Spectrin antibody (MAB1622) primary antibody, testosterone 3-(O-carboxymethyl) oxime:BSA-fluorescein iso thiocyanate conjugate (T-BSA-FITC, #T5771), nystatin (#N6803), Millicell EZ Slide #PEZGS0816, and N27 rat dopaminergic neural cell line (#SCC048) were purchased from Millipore Sigma. DMSO, MTT (#97062-380), 30% hydrogen
peroxide ($\text{H}_2\text{O}_2$, EM1.07209.0250), RPMI 1640 and Penicillin-streptomycin (PS) were purchased from VWR Life Science. Fetal Bovine Serum (FBS) and phosphate buffer solution (PBS) were obtained from Corning. Charcoal-stripped Fetal Bovine Serum (CS-FBS) was purchased from Atlanta Biologicals. Pierce BCA Protein Assay Kit (23225), tris-buffered saline (TBS, BP2471), and Tween-20 (BP337), Nonidet P-40 lysis buffer, SuperSignal West Pico/Femto chemiluminescent substrates, dithiothreitol (DTT), and protease and phosphatase inhibitor cocktail (PI78442) were obtained from Thermo Fisher Scientific. Rat total cholesterol ELISA (MBS846775) was purchased from MyBioSource. VECTASHIELD antifade mounting medium with DAPI (H-1200-10) from Vector Laboratories. Tris, Any KD polyacrylamide gel, Tris-glycine buffer, PVDF membranes, CAV1 primer (PrimePCR #10025636), GAPDH primer (PrimePCR #10025636), iTaq SYBR Green PCR Master mix (#1725121) were purchased from BioRad. High-Capacity cDNA Reverse Transcriptase Kit (#010961510) was obtained from Applied Biosystems.

Testosterone was dissolved using an ethanol vehicle (final concentration of ethanol < 0.001%, 200 uM). Consistent with other studies showing that <0.1% ethanol has minimal to no impact on cell OS generation and viability (30-32), our studies show that this concentration of ethanol has no impact on cell viability or androgen’s actions (33-35). Further, this concentration of ethanol (17 uM or 17.17 mM/L) is 176-fold below the ethanol concentration (3-30 mM) needed for activation of GABA receptors (36-41). Since little to no albumin is present in healthy brains (42), hormones in the brain are not protein bound and considered free. In order to compensate for the albumin (2.1 g/dl) in the CS-FBS, we used the Vermeulen calculation to determine the appropriate hormone dosage to attain physiological brain hormone levels (43,44). Therefore, in CS-FBS 100 nM of testosterone is equivalent to 8 nM calculated free testosterone, which is consistent with LC-MS/MS brain testosterone levels in male rats (5-24 nM) (45-48).
Cell Culture

The immortalized neuronal cell line (N27; RRID:CVC_L_D584) was derived from female fetal rat mesencephalic tissue. The N27 cell line is positive for tyrosine hydroxylase (TH+) expression, an enzyme marker for dopamine neurons (49-52). This cell line is also positive for the mAR-AR45, estrogen receptor alpha, and estrogen receptor beta but does not express full-length androgen receptors (17,34). N27 cells were cultured and maintained at 37°C in 5% CO2. Media used was RPMI 1640 medium supplemented with 10% FBS and 1% PS. N27 cells were only used within passages 13-19 to avoid changes in morphology.

Experimental Design

N27 cells were plated onto 96-well and 6-well plates with RPMI 1640 media supplemented with 10% FBS and 1% penicillin/streptomycin and incubated to proliferate for 24 hours at 37°C, 5% CO2. Three hours prior to treatment for experimentation, the media was switched to RPMI 1640 with CS-FBS in all treatment and control groups to avoid confounding effects due to the presence of hormones in the serum. We have previously shown that CS-FBS does not impact cell viability or androgen actions (17,34). Maintaining cells in CS-FBS does not negatively impact cell viability, as the media still contains salt, glucose, amino acids, and other nutrients (33-35). The use of CS-FBS will impact only non-genomic hormone action but not impact genomic or transcriptional hormone action which occur on a longer time frame.

Cells at 80% confluence were either exposed to vehicle (media alone) or hydrogen peroxide (H2O2; 18 uM-30 uM) as an oxidative stressor for two hours prior to a 24-hour treatment period of androgen exposure (100 nM testosterone equivalent to 8 nM calculated free testosterone). This concentration of H2O2 was sufficient to induce 20% cell loss and achieve the OS threshold necessary to see androgen’s negative effects on cells. Cells were exposed to nystatin (50-75 uM) 1 hour after H2O2 treatment and
then treated with androgens or vehicle. Following treatments, cells were analyzed for cell viability or protein expression of various markers. For cell viability experiments, 50 uM nystatin was used as this dose was sufficient to observe a functional effect. However, 75 uM nystatin was used for western blot protein analysis experiments as this dose was sufficient to consistently decrease caveolin-1 protein expression. The differences in nystatin dose is due to the sensitivity of the assays, in which MTT is a functional assay and more sensitive to changes than structural protein assays.

Cell Viability

Cell viability was determined by MTT assay. Media was aspirated from all wells, replenished with 100 uL of RPMI-1640 phenol red-free medium, and supplemented with 10% CS-FBS, 1% PS, and 1% l-glutamine. This was followed by the addition of 20 uL of 5 mg/mL of MTT solution to each well. Experimental plates were then covered in foil to block additional light and incubated at 37°C with 5% CO2 for 3 h. Following incubation, MTT reagent was removed and replaced with 100 ul DMSO to solubilize the precipitate. Following 1 hour of agitation, plates were read at an absorbance of 595 nm. The colorimetric intensity is directly proportional to the number of viable cells in each well. Readings from different treatment groups were then normalized to the control group to determine cell viability. At least three different experiments were conducted; each n is a mean of eight wells per treatment group on one plate.

Cell lysates and Homogenization

After treatments were carried out as stated in the experimental design, cells were placed on ice, washed with PBS, and lysed using Nonidet P-40 lysis buffer with a cocktail of dithiothreitol (1 µM), EDTA (1 mM), phosphatase and protease inhibitor cocktail (1:200). The lysates were homogenized and centrifuged at 12,753 rpm at 4°C for 20 minutes. The supernatant was then collected, and protein
concentrations were measured using the Pierce BCA protein assay kit, according to the manufacturer’s instructions.

**Western Blot**

Equal amounts of (30 ug protein) denatured whole cell lysates were loaded into a Bio-Rad Any KD polyacrylamide gel, electrophoresed in a Tris-glycine buffer. Proteins were separated by SDS-PAGE at room temperature at 25 mA. Next, proteins were transferred for 2-3 hours at 80 V onto a polyvinylidene difluoride (PVDF) membrane at 4°C. Membranes were washed 3 times for 10 minutes each under agitation with Tris-buffered saline with Tween 20 (TBST) and then, membranes were blocked for 1 hour with 5% nonfat milk in TBS-Tween at room temperature. Following blocking, the membranes were incubated with specific primary antibodies (AR C-19 1:1000 to examine the mAR, AR N-20 1:1000 to examine full-length androgen receptor, aromatase 1:1000, ER MC-20 1:1000 to examine estrogen receptor alpha, Spectrin 1:1000 to examine caspase-3 activity, Beta Actin 1: 2000 for protein normalization, and caveolin-1 1: 1000 to examine lipid rafts) in TBS-Tween with 1% nonfat milk overnight in 4°C. Afterward, the membranes were washed every 10-minutes for 30 minutes and then incubated with secondary antibodies (1:5000 dilution for goat anti-rabbit and goat anti-mouse) in TBS-Tween with 1% nonfat milk for 30 minutes at room temperature. After washing membranes three times for 30 minutes, protein bands on the membrane were visualized using an enhanced chemiluminescence detection assay (Thermo Fisher Scientific). Protein band intensities were imaged using GeneSys software corresponding with the Syngene G-Box Chemi XRQ system. Protein band densities were quantified by NIH Image J densitometer software and normalized to Beta Actin for whole cell lysates.
Immunocytochemistry

N27 cells were plated in eight-well glass slides (Millicell EZ Slide) at a density of $3.0 \times 10^4$ cells in each well. Cells were fixed after treatment exposures (testosterone-BSA-FITC). The cells on the slides were washed with cold 1X PMS twice for 1 minute each followed by 100% cold methanol fixation in the −20°C for 10 minutes. Afterwards, the slides were washed with 1X cold PBS, and then sealed with mounting VECTASHIELD medium containing DAPI. Once sealed with coverslips, the slides were stored at 4°C. A fluorescence microscope (Olympus BX41, Olympus Corporation) equipped with wide UV and FITC filters was used to visualize fluorescence of the cells on the slides. Images of the cells at 40X magnification were captured using a digital camera (Olympus DP70, Olympus Corporation) and imaging software (DP Controller - version 3.3.1.292 and DP Manager - version 3.3.1.222, Olympus Corporation).

Cholesterol ELISA

Total cellular cholesterol levels were assayed by ELISA using a commercially available kit (MBS846775, MyBioSource) according to manufacturer’s instructions. The detection range was 0.3-28 nmol/ml. The intra-assay coefficient of variation is <10% and the inter-assay coefficient of variation is <12%. The sensitivity of this assay is < 0.1 nmol/ml. N27 cells were incubated with nystatin (30-75 uM) overnight for 18 hours prior to processing for ELISA.

Quantitative Real-Time PCR (qPCR)

To examine caveolin-1 mRNA expression in our study, we used a relative quantitative real-time PCR method to amplify caveolin-1. This method compares changes in gene expression between vehicle control and nystatin treated samples. Total RNA was extracted from N27 cells via Trizol extraction (Invitrogen). RNA concentrations were measured with a NanoDrop-One Microvolume UV-Vis Spectrophotometer (ThermoFisher), and 1 µg was reverse transcribed using the High-Capacity cDNA
Reverse Transcriptase Kit. The resulting cDNA was analyzed using the BioRad CFX Connect real-time PCR system. Each reaction included iTaq SYBR Green PCR Master mix, 30ng of cDNA, Caveolin-1 primer or GAPDH primer. Expression of Caveolin-1 mRNA was normalized to GAPDH mRNA that was used as internal control. Quantification of PCR amplified mRNA specific cDNA was done by comparative cycle threshold CT method (2^\(-\Delta\Delta CT\)).

Statistical Analysis

Analysis was performed using IBM SPSS Statistics version 21 software. Shapiro-Wilk test was used to test for normality of data, whereas Levene’s test was used to examine homogeneity of variances. Control groups in cell viability and western blot experiments were normalized to 100% and this caused normality to be affected only in this group. Since the majority of treatment groups in each experiment were normally distributed and all groups were homogenous, the use of parametric statistics was appropriate. Therefore, an ANOVA, using independent factors of oxidative stress, testosterone, and nystatin was used. Tukey’s HSD was used as a post-hoc analysis in this study. Data were expressed as mean ± SEM. Significance was set at p ≤ 0.05.

Results

Nystatin and cholesterol levels

In these experiments, we used nystatin to sequester cholesterol (29) in order to decrease plasma membrane lipid raft expression (53). To ensure that nystatin does not impact cellular cholesterol levels, we quantified cholesterol levels following a nystatin dose response curve (30-75 uM nystatin). Our results showed that nystatin did not alter cellular cholesterol levels (F\(_{3,8}\) = 0.010, p > 0.05), regardless of the amount of nystatin used (Figure 1A). Next, we conducted a dose-response curve (0-150 uM nystatin) to determine nystatin’s effects on cell viability. Our results showed that cell viability was unaffected by nystatin (F\(_{3,12}\) = 2.541, p > 0.05 (Figure 1B).
Sequestering cholesterol blocked testosterone’s negative effects in an oxidative stress environment

Cholesterol sequestration can alter the composition of the caveolar lipid rafts, which can alter the function of receptors localized to lipid rafts (19,54,55). Since the mAR, AR45 (i.e., 45 kDa MW), resides within a caveolin-1 lipid raft (18), we used nystatin to impact mAR function. We exposed N27 cells to the oxidative stressor, H$_2$O$_2$, to induce 20-30% cell loss. An OS burden of 20-30% cell loss is necessary to observe testosterone’s neurotoxic effects instead of testosterone’s neuroprotective effects (17). H$_2$O$_2$ decreased cell viability ($F_{1,16} = 199.385$, $p < 0.05$), and this effect was exacerbated by testosterone exposure as evidenced by a significant interaction between testosterone and OS ($F_{1,16} = 7.114$, $p < 0.05$) (Figure 2). Nystatin (50 uM) blocked testosterone’s negative effects on cell viability in an OS environment ($F_{5,16} = 5.175$, $p < 0.05$). Therefore, when cells are pretreated with nystatin to sequester cholesterol, testosterone was unable to exacerbate H$_2$O$_2$-induced cell loss. These results support the role of testosterone acting through a mAR localized within a cholesterol-rich lipid raft.

Nystatin decreased caveolin-1 lipid rafts and membrane androgen receptors

To determine the role of caveolin-1 lipid rafts and mAR on OS, we quantified protein and mRNA expression of caveolin-1, which is a plasma membrane protein. Neither OS ($F_{1,40} = 0.416$, $p > 0.05$) nor testosterone ($F_{1,40} = 0.087$, $p > 0.05$) impacted caveolin-1 protein expression in N27 cells (Figure 3A, C). As expected, nystatin (75 uM) decreased caveolin-1 expression ($F_{1,40} = 133.504$, $p < 0.05$). These results showed that nystatin decreased caveolin-1 lipid rafts, regardless of OS or hormone treatment. Since nystatin decreased caveolin-1 protein expression, we examined if cholesterol sequestering impacted caveolin-1 translation by quantifying caveolin-1 mRNA levels (Figure 3B). Our results show that nystatin decreased caveolin-1 transcription in N27 cells ($F_{1,4} = 2007.35$, $p < 0.05$).
Since nystatin decreased caveolar lipid rafts, we examined the impact of nystatin on mAR-AR45 protein expression. Neither OS (F$_{1,40}$ = 0.195, p > 0.05) nor testosterone (F$_{1,40}$ = 0.031, p > 0.05) altered mAR expression in N27 cells, which is consistent with our previous studies (18,20). However, nystatin (75 uM) decreased mAR protein expression (F$_{1,40}$ = 96.451, p < 0.05), regardless of OS environment (Figure 3 A, D). These results indicate that the loss of lipid rafts by nystatin also resulted in the loss of mAR that resides within lipid rafts. Consistent with our prior studies (17,18), N27 cells do not express full-length androgen receptors (Figure 3A), as evidenced by the lack of immunoreactivity at 110 kDa molecular weight using a C-terminus androgen receptor antibody. We also examined immunoreactivity to a N-terminus androgen receptor antibody (androgen receptor N-20 antibody), in which immunoreactivity should be observed if full-length androgen receptors (110 kDa) are present. No immunoreactivity was observed with a N-terminus androgen receptor antibody at either the 110 kDa or the 45 kDa molecular weight (Figure 3A), further supporting the lack of full-length androgen receptors and only the presence of the mAR-AR45 that does not contain a N-terminus region.

**Nystatin does not impact estrogen receptor or aromatase expression**

Our prior studies have shown that neither inhibition of cytosolic androgen receptors nor estrogen receptors blocked testosterone’s negative actions on cell viability in an OS environment (17,20,33). However, the role of nystatin on estrogen receptor expression is unknown. Similarly, the role of nystatin on aromatase, the enzyme that metabolizes testosterone to estradiol, is unknown. Our results in Figure 4 show that nystatin (75 uM) does not impact estrogen receptor alpha expression (F$_{1,4}$ = 0.067, p > 0.05) or aromatase expression (F$_{1,4}$ = 0.013, p > 0.05), even though nystatin significantly decreased caveolin-1 lipid rafts (F$_{1,4}$ = 12.232, p < 0.05).
**Cholesterol sequestering decreased endocytosis of membrane androgen receptors**

Caveolar lipid rafts are involved in multiple functions, such as intracellular signaling and endocytosis (19,56). In prostate cells and Sertoli cells, endocytosis or internalization of the mAR via a caveolin-1 mechanism has been observed (57-59). Currently, only the mAR-AR45 has been found in caveolin lipid rafts in neuronal tissues in rats and humans (17,18), but it is unknown if this mAR is involved in endocytosis. To examine if caveolin-1 lipid rafts internalize testosterone via the mAR, we used a FITC-tagged testosterone-conjugated to the cell impermeable bovine serum albumin (T-BSA) to restrict its activity to the mAR (17,33). Within 30 minutes, T-BSA was internalized within N27 cells (Figure 5). Nystatin (75 uM) blocked the internalization of T-BSA, indicating that mAR localized to caveolar lipid rafts in the plasma membrane of neuronal cells are involved in endocytosis.

**Nystatin decreased apoptosis in oxidative stressed N27 cells exposed to testosterone**

Our prior studies show that testosterone exacerbation of OS induced cell loss is via an apoptotic mechanism (33,60). Since nystatin decreased testosterone’s negative effects on cell viability in an OS environment, we examined if nystatin (75 uM) decreases testosterone induced caspase-3 mediated apoptosis in an OS environment in Figure 6. OS (H₂O₂) significantly increased caspase-3 mediated apoptosis in N27 cells (F₁,40 = 209.50, p < 0.05), which was exacerbated by testosterone exposure (F₁,40 = 13.15, p < 0.05). However, this effect of testosterone in an OS environment was blocked by sequestering cholesterol in the cells with nystatin (F₁,40 = 3.121, p > 0.05).

**Discussion**

The major findings of this study are 1) cholesterol sequestering blocks testosterone exacerbation of OS induced apoptotic cell loss, 2) cholesterol sequestering decreases caveolin-1 lipid rafts, resulting in decreased mAR expression and endocytosis, and 3) cholesterol sequestering does not impact either estrogen receptor or aromatase protein expression, suggesting that cholesterol sequestering or altering
lipid raft expression does not impact estrogen signaling. These findings indicate that localization of the mAR-AR45 to cholesterol-rich lipid rafts is necessary for testosterone’s neurotoxic effects in an OS environment. Thus, mAR mediated endocytosis and apoptosis may be involved in neurodegenerative diseases associated with OS, which is consistent with our previous studies that found testosterone is associated with cognitive impairment in aged men with elevated OS (61).

This is the first study to show that lipid rafts are necessary for testosterone’s neurotoxic effects in an OS environment. Our previous studies have shown that degrading the mAR-AR45 was sufficient to block testosterone’s activation of OS signaling through the NADPH oxidase signaling cascade (20). However, inhibition of androgen receptors may not be clinically appropriate as androgens also have neuroprotective effects (62), and the loss of these neuroprotective actions of testosterone could negatively impact health. Therefore, the purpose of these experiments was to determine how to interfere with androgen’s neurotoxic effects in an OS environment without impacting overall androgen signaling. Our results show that decreasing mARs by decreasing cholesterol-rich lipid rafts blocked the neurotoxic effects of androgens in an OS environment. These results suggest that cholesterol sequestering by statins may have a beneficial effect in individuals that exhibit elevated OS and androgens.

Even though the mechanisms of statin-associated neuroprotection are not well understood (63), lipophilic statins can impact brain function. Currently, there are no studies published on the uptake, distribution, and metabolism of statins in the brain, but lipophilic statins can cross the blood brain barrier (BBB) more freely than hydrophilic statins by passive diffusion (26,64). Indeed, studies using the in-situ rat brain perfusion technique observed increased radiolabeled lipophilic statins (Lovastatin and Simvastatin) in rat cerebral cortical brain tissue, indicating that lipophilic statins can cross the BBB (63). However, this effect on the BBB was not observed with the radiolabeled hydrophilic statin,
Pravastatin (63). Therefore, one potential mechanism of action for statin-associated neuroprotection could be the ability of statins to cross the BBB.

The impact of lipophilicity of statins on neuroprotection was observed in both large retrospective cohort studies and cross-sectional studies, which found an association between the lipophilic statins (e.g., Lovastatin, Simvastatin, Atorvastatin) and decreased incidence of dementia (28,65).

Interestingly, race and sex may play a role in lipophilic statin-associated decreased dementia. Studies using lipophilic statins found an association with decreased dementia risk in Caucasian and Hispanic men and women, along with Black women (26,66). In contrast, statins have not been associated with a reduction of dementia risk in Black men, regardless of lipophilicity (26). More studies need to be conducted to examine the influence of sex and race on statin neuroprotection, as statins could have different effects on dementia risk in diverse patient populations. Generally, statin concentrations range between 100 nM and 1 µM in studies showing a neuroprotective benefit (63).

This study provided evidence that cholesterol is essential for mAR-AR45 cell signaling. Nystatin, a cholesterol sequestering agent (29), was used to determine whether sequestering of cholesterol to decrease lipid rafts can alter cell signaling through the mAR and improve cell survival. Indeed, nystatin sequestered the cholesterol and decreased caveolar lipid rafts. This loss of caveolar lipid rafts blocked the negative effects of testosterone on cell viability in an OS environment, indicating that the cholesterol-rich lipid rafts are necessary for mARs for androgen’s neurotoxic effects. Notably, only mAR-AR45 expression, and not estrogen receptor or aromatase expression, was impacted by loss of caveolin-1 lipid rafts, further supporting the role of lipid raft associated mARs mediating testosterone’s negative effects in and OS environment.
Cholesterol is involved in the steroidogenesis of steroid hormones including androgens (67). Although statins can lower plasma cholesterol levels (68,69), prior studies have found that statins do not impact androgen production and serum androgen levels (23). This was shown in a population-based, cross-sectional epidemiologic study which was carried out among 5,506 men and women between ages 30 to 79 who were diagnosed with cardiovascular diseases (23). Each participant was treated with statins, which included atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Before and after the study, testosterone, sex hormone–binding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS) levels were measured, and results showed that therapeutic concentrations of statins do not impact androgen synthesis and androgen serum levels (23). Similarly, statins have been shown to not impact estrogen (i.e., 17β-estradiol and estrone) serum levels (70,71). It has been suggested that the mechanisms by which prostatic tissue maintains tissue androgen levels may include metabolism of androgens in the adrenal glands or by de novo synthesis from cholesterol (23).

Our study has many strengths, which include using in vitro models to study the effects of cholesterol on androgen’s neurotoxic effects in a high OS environment. A major limitation in this study is that we did not include a male (XY) cell line to compare against the findings in the N27 female (XX) cell line. However, we previously published that testosterone and its metabolite dihydrotestosterone in an OS environment negatively impacts cell viability through the mAR, regardless of the sex (XX vs XY) of the cells using N27 cells and PC12 cells that are derived from rats (17).

A few epidemiological studies have examined the efficacy of statins in treating dementia (72). While some studies have shown success for statins to decrease the risk of dementia (73), others have not (74,75). Epidemiological studies may be more successful in showing a decrease in the risk of dementia after statin use if sex and gonadal hormone status are independently examined. Our results suggest that cholesterol-lowering agents, such as statins, may be a useful therapeutic agent for OS associated neurodegenerative diseases.
Declaration of Interest

None

Funding

This study was supported by NIH R01 NS0091359 to RLC.

Author contributions

OF conducted experiments, analyzed the data, interpreted the findings, and was a major contributor in writing the manuscript. NR, SM, and DHN conducted experiments and analyzed the data. RLC designed the study, interpreted the findings, and was a major contributor to the writing of the manuscript. RLC has full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements

We would like to thank E. Nicole Wilson and Rachel Engelland for their technical and editorial assistance.

Data Availability

All data generated or analyzed during this study are included in this published article.
References

1. Kim MY, Kim K, Hong CH, Lee SY, Jung YS. Sex Differences in Cardiovascular Risk Factors for Dementia. Biomol Ther (Seoul). 2018;26(6):521-532.

2. Viña J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis. 2010;20 Suppl 2:S527-533.

3. Sierra C. Hypertension and the Risk of Dementia. Front Cardiovasc Med. 2020;7:5.

4. Rodrigo R, González J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res. 2011;34(4):431-440.

5. Everett B, Zajacova A. Gender differences in hypertension and hypertension awareness among young adults. Biodemography Soc Biol. 2015;61(1):1-17.

6. Dosi R, Bhatt N, Shah P, Patell R. Cardiovascular disease and menopause. J Clin Diagn Res. 2014;8(2):62-64.

7. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World J Cardiol. 2012;4(5):135-147.

8. Yaffe K, Vittinghoff E, Hoang T, Matthews K, Golden SH, Zeki Al Hazzouri A. Cardiovascular Risk Factors Across the Life Course and Cognitive Decline: A Pooled Cohort Study. Neurology. 2021;96(17):e2212-e2219.

9. Walker KA, Power MC, Gottesman RF. Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review. Curr Hypertens Rep. 2017;19(3):24.

10. Kalaria RN. The pathology and pathophysiology of vascular dementia. Neuropharmacology. 2018;134(Pt B):226-239.

11. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713.
12. World Health O. Dementia: a public health priority. Geneva: World Health Organization.

13. Iadecola C. The pathobiology of vascular dementia. *Neuron*. 2013;80(4):844-866.

14. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov*. 2004;3(3):205-214.

15. Borrás C, Gambini J, López-Grueso R, Pallardó FV, Viña J. Direct antioxidant and protective effect of estradiol on isolated mitochondria. *Biochim Biophys Acta*. 2010;1802(1):205-211.

16. Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. *Proc Natl Acad Sci USA*. 1999;96(16):8867-8872.

17. Duong P, Tenkorang MAA, Trieu J, McCuiston C, Rybalchenko N, Cunningham RL. Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment. *Biol Sex Differ*. 2020;11(1):12.

18. Garza-Contreras J, Duong P, Snyder BD, Schreihofer DA, Cunningham RL. Presence of Androgen Receptor Variant in Neuronal Lipid Rafts. *eNeuro*. 2017;4(4).

19. Lajoie P, Nabi IR. Lipid rafts, caveolae, and their endocytosis. *Int Rev Cell Mol Biol*. 2010;282:135-163.

20. Tenkorang MAA, Duong P, Cunningham RL. NADPH Oxidase Mediates Membrane Androgen Receptor-Induced Neurodegeneration. *Endocrinology*. 2019;160(4):947-963.

21. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. *J Clin Invest*. 2002;110(5):597-603.

22. Subhan M, Faryal R, Macreadie I. Exploitation of Aspergillus terreus for the Production of Natural Statins. *J Fungi (Basel)*. 2016;2(2).

23. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, McKinlay JB. Do statins affect androgen levels in men? Results from the Boston area community health survey. *Cancer Epidemiol Biomarkers Prev*. 2007;16(8):1587-1594.

24. Silva T, Teixeira J, Remião F, Borges F. Alzheimer’s disease, cholesterol, and statins: the junctions of important metabolic pathways. *Angew Chem Int Ed Engl*. 2013;52(4):1110-1121.
25. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58(7):1311-1317.

26. Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. JAMA Neurol. 2017;74(2):225-232.

27. Xuan K, Zhao T, Qu G, Liu H, Chen X, Sun Y. The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial. Neurol Sci. 2020;41(6):1391-1404.

28. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018;7:5.

29. Baek S, Kim SM, Lee SA, Rhim BY, Eo SK, Kim K. The cholesterol-binding antibiotic nystatin induces expression of macrophage inflammatory protein-1 in macrophages. Biomol Ther (Seoul). 2013;21(1):42-48.

30. Timm M, Saaby L, Møesby L, Hansen EW. Considerations regarding use of solvents in in vitro cell based assays. Cytotechnology. 2013;65(5):887-894.

31. Forman S, Kás J, Fini F, Steinberg M, Ruml T. The effect of different solvents on the ATP/ADP content and growth properties of HeLa cells. J Biochem Mol Toxicol. 1999;13(1):11-15.

32. Casañas-Sánchez V, Pérez JA, Quinto-Alemany D, Díaz M. Sub-toxic Ethanol Exposure Modulates Gene Expression and Enzyme Activity of Antioxidant Systems to Provide Neuroprotection in Hippocampal HT22 Cells. Frontiers in Physiology. 2016;7(312).

33. Holmes S, Abbassi B, Su C, Singh M, Cunningham RL. Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology. 2013;154(11):4281-4292.

34. Holmes S, Singh M, Su C, Cunningham RL. Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line. Endocrinology. 2016;157(7):2824-2835.
35. Biswas R, Vonderhaar BK. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. *Cancer Res.* 1987;47(13):3509-3514.

36. Morrow AL, Suzdak PD, Paul SM. Benzodiazepine, barbiturate, ethanol and hypnotic steroid hormone modulation of GABA-mediated chloride ion transport in rat brain synaptoneurosomes. *Adv Biochem Psychopharmacol.* 1988;45:247-261.

37. Suzdak PD, Schwartz RD, Skolnick P, Paul SM. Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. *Proc Natl Acad Sci U S A.* 1986;83(11):4071-4075.

38. Suzdak PD, Paul SM. Ethanol stimulates GABA receptor-mediated Cl⁻ ion flux in vitro: possible relationship to the anxiolytic and intoxicating actions of alcohol. *Psychopharmacol Bull.* 1987;23(3):445-451.

39. Ticku MK, Lowrimore P, Lehoullier P. Ethanol enhances GABA-induced 36Cl⁻-influx in primary spinal cord cultured neurons. *Brain Res Bull.* 1986;17(1):123-126.

40. Wallner M, Hanchar HI, Olsen RW. Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. *Proc Natl Acad Sci U S A.* 2003;100(25):15218-15223.

41. Smith SS, Gong QH. Ethanol effects on GABA-gated current in a model of increased alpha4betadelta GABAA receptor expression depend on time course and preexposure to low concentrations of the drug. *Alcohol.* 2007;41(3):223-231.

42. LeVine SM. Albumin and multiple sclerosis. *BMC Neurol.* 2016;16:47.

43. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* 1999;84(10):3666-3672.

44. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol; with illustrative examples from male and female populations. *Steroids.* 2009;74(6):512-519.

45. Okamoto M, Hojo Y, Inoue K, Matsui T, Kawato S, McEwen BS, Soya H. Mild exercise increases dihydrotestosterone in hippocampus providing evidence for androgenic mediation of neurogenesis. *Proc Natl Acad Sci U S A.* 2012;109(32):13100-13105.
46. Higashi T. Trace determination of steroids causing age-related diseases using LC/MS combined with detection-oriented derivatization. *Chem Pharm Bull (Tokyo)*. 2006;54(11):1479-1485.

47. Tobiansky DJ, Korol AM, Ma C, Hamden JE, Jalabert C, Tomm RJ, Soma KK. Testosterone and Corticosterone in the Mesocorticolimbic System of Male Rats: Effects of Gonadectomy and Caloric Restriction. *Endocrinology*. 2018;159(1):450-464.

48. Caruso D, Pesaresi M, Abbiati F, Calabrese D, Giatti S, Garcia-Segura LM, Melcangi RC. Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats. *Psychoneuroendocrinology*. 2013;38(10):2278-2290.

49. Anantharam V, Lehrmann E, Kanthasamy A, Yang Y, Banerjee P, Becker KG, Freed WJ, Kanthasamy AG. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. *Neurochem Int*. 2007;50(6):834-847.

50. Kritzer MF. Selective colocalization of immunoreactivity for intracellular gonadal hormone receptors and tyrosine hydroxylase in the ventral tegmental area, substantia nigra, and retrorubral fields in the rat. *J Comp Neurol*. 1997;379(2):247-260.

51. Carvour M, Song C, Kaul S, Anantharam V, Kanthasamy A, Kanthasamy A. Chronic low-dose oxidative stress induces caspase-3-dependent PKCdelta proteolytic activation and apoptosis in a cell culture model of dopaminergic neurodegeneration. *Ann NY Acad Sci*. 2008;1139:197-205.

52. Clarkson ED, Edwards-Prasad J, Freed CR, Prasad KN. Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection. *Proc Soc Exp Biol Med*. 1999;222(2):157-163.

53. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. *Cell*. 1992;68(4):673-682.

54. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. *J Immunol*. 2011;187(4):1529-1535.
55. Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, Fessler MB, Parks JS. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. *J Lipid Res.* 2010;51(11):3196-3206.

56. Parton RG, Simons K. The multiple faces of caveolae. *Nat Rev Mol Cell Biol.* 2007;8(3):185-194.

57. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. *J Biol Chem.* 2001;276(16):13442-13451.

58. Deng Q, Wu Y, Zhang Z, Wang Y, Li M, Liang H, Gui Y. Androgen Receptor Localizes to Plasma Membrane by Binding to Caveolin-1 in Mouse Sertoli Cells. *Int J Endocrinol.* 2017;2017:3985916.

59. Li J, Fu X, Cao S, Li J, Xing S, Li D, Dong Y, Cardin D, Park HW, Mauvais-Jarvis F, Zhang H. Membrane-associated androgen receptor (AR) potentiates its transcriptional activities by activating heat shock protein 27 (HSP27). *J Biol Chem.* 2018;293(33):12719-12729.

60. Snyder B, Duong P, Trieu J, Cunningham RL. Androgens modulate chronic intermittent hypoxia effects on brain and behavior. *Horm Behav.* 2018;106:62-73.

61. Cunningham RL, Singh M, O’Bryant SE, Hall JR, Barber RC. Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer’s disease. *J Alzheimers Dis.* 2014;40(3):563-573.

62. Białek M, Zaremba P, Borowicz KK, Czuczwar SJ. Neuroprotective role of testosterone in the nervous system. *Pol J Pharmacol.* 2004;56(5):509-518.

63. Wood WG, Eckert GP, Igbavboa U, Müller WE. Statins and neuroprotection: a prescription to move the field forward. *Ann N Y Acad Sci.* 2010;1199:69-76.

64. Mulder KC, Mulinari F, Franco OL, Soares MS, Magalhães BS, Parachin NS. Lovastatin production: From molecular basis to industrial process optimization. *Biotechnol Adv.* 2015;33(6 Pt 1):648-665.
65. Wolozin B, Kellman W, Ruoseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol.* 2000;57(10):1439-1443.

66. Pfefferkorn JA, Song Y, Sun KL, Miller SR, Trivedi BK, Choi C, Sorenson RJ, Bratton LD, Unangst PC, Larsen SD, Poel TJ, Cheng XM, Lee C, Erasga N, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Olsen K, Mertz T, Sekerke C, Pavlovsky A, Harris MS, Bainbridge G, Caspers N, Chen H, Eberstadt M. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. *Bioorg Med Chem Lett.* 2007;17(16):4538-4544.

67. Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. *J Lipid Res.* 2011;52(12):2111-2135.

68. Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. *Curr Opin Lipidol.* 2019;30(5):388-394.

69. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrière B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2021, MDText.com, Inc.; 2000.

70. Peck A, Chaikittisilpa S, Mirzaei R, Wang J, Mack WJ, Hodis HN, Stanczyk FZ. Effect of statins on estrogen and androgen levels in postmenopausal women treated with estradiol. *Climacteric.* 2011;14(1):49-53.

71. Oluleye OW, Kronmal RA, Folsom AR, Vaidya DM, Ouyang P, Duprez DA, Dobs AS, Yarmohammadi H, Konety SH. Association Between Statin Use and Sex Hormone in the Multi-Ethnic Study of Atherosclerosis Cohort. *The Journal of Clinical Endocrinology & Metabolism.* 2019;104(10):4600-4606.
72. Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. *Alzheimers Res Ther*. 2017;9(1):10.

73. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. *Neurology*. 2008;71(5):344-350.

74. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. *Arch Neurol*. 2011;68(10):1239-1244.

75. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. *Arch Neurol*. 2011;68(11):1385-1392.
Figure Legends

Figure 1: **Nystatin and cholesterol concentration.** Treatment with nystatin (18 hours overnight) does not alter cholesterol concentration, regardless of the concentration (A), nor does it impact cell viability (B). n=3 in Panel A and n=4 in Panel B.

Figure 2: **Impact of cholesterol sequestering on testosterone exacerbation of oxidative stress induced cell death.** Neither testosterone (100 nM testosterone equivalent to 8 nM calculated free testosterone) nor nystatin (50 uM) altered cell viability. In contrast, testosterone exacerbated H$_2$O$_2$-induced cell loss. Cholesterol sequestering via nystatin blocked testosterone exacerbation of H$_2$O$_2$-induced cell loss. T: Testosterone; Nyst: Nystatin. ** P < 0.05: oxidative stress (H$_2$O$_2$ treated) vs. no oxidative stress (not H$_2$O$_2$ treated); * P < 0.05: vs other treatments. n=3.

Figure 3: **Cholesterol sequestering decreased caveolin-1 expression and mAR-AR45 expression.** Neither H$_2$O$_2$ nor testosterone (100 nM) altered caveolin-1 lipid raft protein expression. Cholesterol sequestering by nystatin (75 uM) decreased caveolin-1 expression (A, C). Nystatin decreased transcription of caveolin-1 mRNA (B). Cholesterol sequestering by nystatin decreased mAR (AR45) expression (A, D). N27 cells do not express full-length androgen receptors, as indicated by the lack of immunoreactivity at 110 kD. Further, AR45 lacks a N-terminus domain (NTD), and this protein can only be observed with a C-terminus domain (CTD) androgen receptor antibody (C-19) and not a N-terminus domain androgen receptor antibody (N-20) (A). V: Vehicle; T: Testosterone; Nyst/N: Nystatin. * P < 0.05: vs non-nystatin treatment groups. N=3 for Panel B and n=6 for the other panels.
Figure 4: Cholesterol sequestering does not impact estrogen receptors or aromatase. Cholesterol sequestering by nystatin (75 uM) does not impact estrogen receptor alpha expression (A, C) or aromatase expression (B, D), even though it does decrease caveolin-1 expression (A, B, D). V: Vehicle; Nyst: Nystatin. * P ≤ 0.05: vs vehicle. n=3.

Figure 5: Cholesterol sequestering blocked membrane androgen receptor mediated endocytosis. N27 cells were exposed to either 0 uM (negative control) or 5 uM testosterone-BSA-FITC (T-BSA) to examine internalization of a cell impermeable androgen that is restricted to membrane androgen receptor activation. Within 30 minutes of T-BSA exposure, internalization of T-BSA via membrane androgen receptors occurs. This effect is sustained for at least two hours (120 min T-BSA). Pretreatment with nystatin (75 uM overnight) blocked T-BSA internalization (endocytosis). DAPI-label nuclear staining (blue) and T-BSA-FITC fluorescence (green). n=3. Scale bar = 50 um.

Figure 6: Cholesterol sequestering blocked testosterone exacerbation of oxidative stress induced apoptosis. Caspase-3 is the primary executor of apoptotic cell death. Caspase-3 activity can be quantified by measure cleavage of cytoskeletal protein, Spectrin, at 125 kD. In the absence of oxidative stress, neither testosterone nor nystatin (75 uM) increased caspase-3 activity compared to vehicle control. As expected, H₂O₂ oxidative stress increased caspase-3 activity. Testosterone exacerbated H₂O₂ induced caspase-3 activity. Sequestering of cholesterol by nystatin blocked testosterone exacerbation of H₂O₂ induced caspase-3 activity. V: Vehicle; T: Testosterone; Nyst/N: Nystatin. ** P ≤ 0.05: oxidative stress vs. no oxidative stress; * P ≤ 0.05: vs other treatments. n=6.
Figure 1

A. 

Cholesterol (nmol/ml) 

Control | 30 uM Nystatin | 50 uM Nystatin | 75 uM Nystatin

B. 

Cell Viability (% of Control) 

0 uM Nystatin | 50 uM Nystatin | 100 uM Nystatin | 150 uM Nystatin
Figure 2

Cell Viability (% of Control)

No Oxidative Stress

Oxidative Stress (H2O2)
Figure 3

A. Immunoblot analysis

B. Caveolin mRNA expression

C. Caveolin-1 expression in different conditions

D. Membrane Androgen Receptor AR45 expression in different conditions
Figure 4

A. 66 kD ER alpha
   23 kD Caveolin-1
   43 kD Actin

B. 55 kD Aromatase
   23 kD Caveolin-1
   43 kD Actin

C. Estrogen Receptor Alpha (% of Control)
   V  Nyst

D. Aromatase (% of Control)
   V  Nyst

E. Caveolin-1 (% of Control)
   V  Nyst

*
Figure 5

Control 30 min T-BSA 90 min T-BSA

120 min T-BSA Nystatin (75 uM) Nystatin + 120 min T-BSA
